2 out of 3 approved anticancer drugs in the EU do not improve survival...

 Global annual spending on cancer drugs has hit $100bn for the first time in history. But are these new and approved drugs providing survival benefits for patients? 

Global annual spending on cancer drugs has hit $100bn for the first time in history. But are these new and approved drugs providing survival benefits for patients? 

From 2009 to 2013, the EMA approved the use of 48 cancer drugs for 68 indications. The majority of these approved cancer drugs entered the market without clear evidence that they improved survival or quality of life for patients. Huseyin Naci, assistant professor of health policy at the London School of Economics has published evidence relating to a retrospective cohort study of drug approvals and their true benefits to patients and society. OvaCure accelerates clinical trial projects that have the potential to cure by increasing both overall survival and quality of life for patients. OvaCure believes that the best clinical outcomes will be achieved with personalised care. It is our hope that these endpoints will be prioritised by global regulatory agents, academia and industry when considering new clinical trial design and drug development.